Sign In
Buy DNLI
$19.66
+0.310 (+1.60%)
At Close: Jun 03, 2026
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Buy” from Analysts
01:28am, Saturday, 14'th Feb 2026
Shares of Denali Therapeutics Inc. (NASDAQ: DNLI - Get Free Report) have earned an average recommendation of "Buy" from the fourteen brokerages that are presently covering the company, Marketbeat.com
Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript
04:14pm, Friday, 06'th Feb 2026
Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced data from programs in Hunter syndrome (mucopolysaccharidosis type II, MPS II), Sa
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates
11:02am, Tuesday, 03'rd Feb 2026
Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
08:00am, Monday, 02'nd Feb 2026
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that management will host a live webcast to review presentations on its Enzyme Tr
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the presentation of clinical and preclinical data from its Enzyme TransportVehicl
Head to Head Comparison: Ultragenyx Pharmaceutical (NASDAQ:RARE) and Denali Therapeutics (NASDAQ:DNLI)
03:13am, Wednesday, 28'th Jan 2026
Ultragenyx Pharmaceutical (NASDAQ: RARE - Get Free Report) and Denali Therapeutics (NASDAQ: DNLI - Get Free Report) are both mid-cap medical companies, but which is the better investment? We will cont
SG Americas Securities LLC Invests $555,000 in Denali Therapeutics Inc. $DNLI
05:14am, Saturday, 24'th Jan 2026
SG Americas Securities LLC purchased a new position in Denali Therapeutics Inc. (NASDAQ: DNLI) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. Th
3 Biotech Stocks That Could Double In 2026
10:42am, Tuesday, 20'th Jan 2026
The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the m
Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
12:45am, Wednesday, 14'th Jan 2026
Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Denali Therapeutics (NASDAQ:DNLI) Insider Sells $284,097.00 in Stock
04:56am, Sunday, 11'th Jan 2026
Denali Therapeutics Inc. (NASDAQ: DNLI - Get Free Report) insider Alexander Schuth sold 17,218 shares of the stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an aver
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up
02:06pm, Wednesday, 07'th Jan 2026
DNLI maps 2026 goals as it awaits FDA action on tividenofusp alfa, targeting first commercial validation amid multiple late-stage readouts.
SOUTH SAN FRANCISCO, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the publication of results from the open-label Phase 1/2 clinical trial of its in
3 Biotech Stocks With Major 2026 Catalysts
10:15am, Monday, 29'th Dec 2025
Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts lined up for 2026.
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Rating of “Buy” by Brokerages
02:18am, Friday, 26'th Dec 2025
Shares of Denali Therapeutics Inc. (NASDAQ: DNLI - Get Free Report) have received an average rating of "Buy" from the sixteen analysts that are presently covering the firm, MarketBeat.com reports. One
